Burkina Faso begins vaccinations in RTS,S Phase 3 trial

Nanoro is one of 11 trial sites in seven African countries
Read more »

A mother holds her daughter as she receives the first jab of the RTS,S Phase 3 trial

Partnering with us

We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

portfolio graphic thumbnailMVI maintains a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.

View the portfolio »

What we do and how we do it

MVI provides funding and technical support to partners worldwide to accelerate the development of malaria vaccines. MVI also works to ensure that malaria vaccines will reach those who need them.

Read more »

Photo: MVI/ David Poland

News and announcements

 

MVI announces collaboration to explore transmission-blocking vaccines

MVI is working with the Johns Hopkins Bloomberg School of Public Health and the Sabin Vaccine Institute to study the feasibility of developing a transmission-blocking vaccine.

 

Bill Gates: Malaria eradication will almost certainly require vaccine

In his 2010 annual letter, Bill Gates notes the importance of a malaria vaccine to the ultimate goal of eradication.

 

Gates Foundation commended on plan to fund vaccine innovation and delivery

PATH president and CEO said the commitment will have a large impact on children and families in the poorest areas of the world.

 

More news »